San Diego-primarily based Viking Therapeutics marked itself as a serious competitor within the weight loss drug market in February just after revealing promising facts from the mid-stage trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when specified to be a weekly injection and in March the